News

Press Releases

Asuragen’s Xpansion Interpreter® Test Study of 1,040 Transmissions of Fragile X Alleles Reveals Personalized Risks for Expansion from Parent to Child
Asuragen and Labceutics Report Results from Pan European Quality Assurance-Modeled Study on Standardization of BCR-ABL1 Monitoring for CML Patients
Asuragen announces publication on standardization of BCR-ABL1 testing on the international scale
Study Finds New Genetic Test Better Predicts Mother’s Risk of Having a Child With Fragile X Syndrome
FDA clears Asuragen’s RNARetain® Pre-analytical RNA Stabilization Device

About

Back To
Top